University of Chicago grants Pinnacle Oncology worldwide rights to use its long site life cycle technology to develop amifostine as a genomic stabilizing agent

University of Chicago

U.S. / Academic

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Pinnacle Biologics Inc.

U.S. / Tools, Services, and Manufacturing

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced